El médico oncólogo y presidente de ISPOR Brasil, Dr. Stephen Stefani, em su participación en ISPOR LatAm hizo un resumen de los diez puntos culminantes de […]
AS REPORTED in The New England Journal of Medicine by Scott J. Antonia, MD, PhD, of H. Lee Moffitt Cancer Center and Research Institute, and colleagues, the phase III PACIFIC […]
In patients with gastric cancer who receive chemotherapy before gastrectomy, resulting in downstaged disease (cN+ ypN0), overall survival is similar to that of patients with natural […]
The FDA approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the treatment of unresectable or metastatic anaplastic thyroid cancer (ATC) with the BRAF V600E […]
The FDA approved daratumumab (Darzalex, Janssen) in combination with VMP (bortezomib [Velcade, Millennium], melphalan and prednisone) for the treatment of patients with newly diagnosed multiple myeloma […]
Novartis announced today that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients […]
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication – the treatment of […]